Johnson & Johnson (JNJ) reported "statistically significant" topline results Tuesday from a phase 3 study evaluating the combination of Rybrevant and Lazcluze as a first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer.
The pharmaceutical company said the combination regimen, which avoids the use of chemotherapy, met the final pre-specified secondary endpoint of overall survival.
It also said the trial demonstrated "clinically meaningful and statistically significant" improvement in overall survival compared with AstraZeneca's (AZN) osimertinib, which it said is the current standard of care.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.